Moberg Pharma AB (FRA:MB8) ROE % Adjusted to Book Value: -1.13% (As of Mar. 2026)


FRA:MB8 Moberg Pharma AB FRA:MB8
59 GF Score
Price €0.81
GF Value €1.07
! 1 Warning Sign
View Full Analysis

What is Moberg Pharma AB ROE % Adjusted to Book Value?

Moberg Pharma AB FRA:MB8 +2.28% 59 ROE % Adjusted to Book Value is -1.13% as of Mar. 2026. GuruFocus rates FRA:MB8 with a GF Score™ of 59/100 and a GF Value™ of €1.07. The stock has 1 warning sign investors should review.

Moberg Pharma AB's ROE % for the quarter that ended in Mar. 2026 was -0.76%. Moberg Pharma AB's PB Ratio for the quarter that ended in Mar. 2026 was 0.67. Moberg Pharma AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -1.13%.

Moberg Pharma AB ROE % Adjusted to Book Value Related Terms

Moberg Pharma AB ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Moberg Pharma AB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moberg Pharma AB ROE % Adjusted to Book Value Chart

Moberg Pharma AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.64 2.61 -8.08 -5.23 -58.80

Moberg Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.32 -7.58 -4.38 -11.07 -1.13

FRA:MB8 vs ZTS, UTHR: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moberg Pharma AB ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's ROE % Adjusted to Book Value falls into.


FRA:MB8
59GF Score
Moberg Pharma AB FRA:MB8
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moberg Pharma AB ROE % Adjusted to Book Value Calculation

Moberg Pharma AB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-38.81% / 0.66
=-58.80%

Moberg Pharma AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-0.76% / 0.67
=-1.13%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -1.13% mean?
Moberg Pharma AB (FRA:MB8) has a ROE % Adjusted to Book Value of -1.13% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Moberg Pharma AB and its competitors.
Is Moberg Pharma AB's ROE % Adjusted to Book Value too high?
Moberg Pharma AB's current ROE % Adjusted to Book Value is -1.13%. Overall, Moberg Pharma AB has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's ROE % Adjusted to Book Value compare to ZTS and UTHR?
Moberg Pharma AB's ROE % Adjusted to Book Value of -1.13% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Moberg Pharma AB and its competitors. Moberg Pharma AB's current ROE % Adjusted to Book Value is -1.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (FRA:MB8) has a current ROE % Adjusted to Book Value of -1.13%. The stock's GF Value™ is €1.07, compared to a current price of €0.81 — trading 24.6% below its estimated fair value. The current ROE % Adjusted to Book Value is -1.13%. Moberg Pharma AB's overall GF Score™ is 59/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current ROE % Adjusted to Book Value is -1.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?

Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued. The current stock price of €0.81 is trading 24.6% below its estimated GF Value™ of €1.07.

Key valuation signals for FRA:MB8:

  • ROE % Adjusted to Book Value: -1.13%
  • GF Value™: €1.07 vs. price of €0.81 (24.6% below fair value)
  • GF Score™: 59/100 with 1 warning sign

No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moberg Pharma AB Business Description

Other Exchanges MBGPF:USAMOB:Sweden
Address Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
59GF Score

Get the complete analysis for FRA:MB8

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.81
Price
€1.07
GF Value